航天控股(00031.HK):接獲有關華保潤訴訟三(高科物業向華保潤就物業管理費拖欠等的訴訟)高科物業上訴的終審判決書
格隆匯11月20日丨航天控股(00031.HK)公佈,公司得悉高科物業於2024年11月19日接獲廣東省深圳市中級人民法院有關華保潤訴訟三(高科物業向華保潤就物業管理費拖欠等的訴訟)高科物業上訴的終審判決書("終審判決"),判決的內容具體如下:
1.駁回上訴,維持原判。
2.二審案件受理費人民幣44,636元,由上訴人高科物業負擔。
誠如公司日期為2024年6月7日和2024年9月4日的公吿所披露之判決結果,預計華保潤需向航天高科和高科物業支付合共約人民幣6860萬元(計算至截至2024年11月19日,最終將按執行情況而定)。上述訴訟為終審判決。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.